| Autor: |
Spirito, Francesca, Nocini, Riccardo, Mori, Giorgio, Albanese, Massimo, Georgakopoulou, Eleni A., Sivaramakrishnan, Gowri, Khalil, Basel, Špiljak, Bruno, Surya, Varun, Mishra, Deepika, Chaurasia, Akhilanand |
| Zdroj: |
International Journal of Molecular Sciences; Dec2024, Vol. 25 Issue 23, p12990, 34p |
| Abstrakt: |
Head and neck cancer (HNC) represents a challenging oncological entity with significant morbidity and mortality rates. Despite advances in conventional therapies, including surgery, chemotherapy, and radiation therapy, the overall survival rates for advanced HNC remain suboptimal. In recent years, the emerging field of oncolytic virotherapy has gained attention as a promising therapeutic approach for various malignancies, including HNC. This review provides a comprehensive overview of the current understanding of oncolytic viruses (Ovs) in the context of HNC treatment, including their mechanisms of action, preclinical and clinical studies, challenges, and future directions. Future oncolytic virotherapy focuses on improving delivery and specificity through nanoparticle carriers and genetic modifications to enhance tumor targeting and immune response. Combining different OVs and integrating them with immunotherapies, such as checkpoint inhibitors, could overcome tumor resistance and improve outcomes. Personalized approaches and rigorous clinical trials are key to ensuring the safety and effectiveness of virotherapy in treating HNC. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
